Eyenovia, Inc. EYEN announced the decision to terminate a phase III study evaluating its investigational drug-device product, ...

In its latest earnings report, Eyenovia highlighted several significant developments, including the advancement of its Phase 3 CHAPERONE study for MicroPine, the launch of clobetasol propionate ...

Pfizer plans to invest $1 billion in China in the next five years. Sun Pharma's JAK inhibitor Leqselvi was slapped with an injunction in a lawsuit with Incyte. And more. 1. UPDATED: AstraZeneca ...

Get detailed information on Clobetasol Propinate, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated ...

Pfizer's diverse operations put it in an excellent position to grow in the long run. It doesn't have a top weight loss treatment on the market, but that could change. Its above-average dividend ...

COURT: C.D. Cal. TRACK DOCKET: No. 5:24-cv-02349 (Bloomberg Law subscription) Pfizer Inc. failed to warn patients that its injectable contraceptive drug Depo-Provera can increase the risk of ...

Pfizer's 14% operational growth in non-COVID products shows the core business is stronger than many believe. The company's oncology franchise has quietly become the industry's third-largest in the ...

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on an operational basis, driven by higher sales of key non-COVID products ...

Pfizer Inc.’s stock was unable to hold its early gains Tuesday and fell 2.4% after the company blew past estimates for the third quarter and raised its full-year guidance. The New York-based ...

With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control ...

Pfizer (NYSE:PFE) shares perked up in the premarket on Tuesday as the New York-based pharma giant beat Street forecasts with its Q3 financials and increased its full-year outlook thanks to ...

Paxlovid on its own drove much of Pfizer’s total sales (PDF) haul of $17.7 billion, up 32% year-over-year. Taking out COVID revenues, the company pulled $13.6 billion in sales in a 14% jump ...